AI Summary

A landmark trial is evaluating whether adding chemotherapy to endocrine therapy benefits patients with high‑risk, early‑stage ER‑positive, HER2‑negative breast cancer who have low genomic risk but high anatomic risk due to large tumors or extensive lymph‑node involvement. The study follows the recent shift to CDK4/6 inhibitors, which have lowered recurrence rates, yet this subgroup still faces uncertainty about the need for chemotherapy. Researchers will assess recurrence outcomes to determine if chemotherapy provides additional benefit for these patients.

AI summaries can be wrong sometimes—always verify important details using the source article.